June 7 - 12, 2008
Macao SAR, China
Venetian Macao Resort Hotel

Programme

Tuesday, June 10

PLENARY SESSIONS

08:30 – 09.30 Ballroom G - L

Plenary Session 2:ISBT Prize lectures
Chairs: S. Takamoto (President of the ISBT), F. Décary (Chair of the Jean Julliard Prize Committee)

08.30 – 09.00
3A-PL2-01 INTERNATIONAL WOMAN IN TRANSFUSION AWARD
Chairs: J. Chapman, representing the BBTS
F. Décary, representing the ISBT

A JOURNEY IN A COMPANY WITH VERY SMALL THINGS: BABIES AND PLATELETS
C. Kaplan (GIP-INTS, Paris, France)

09.00 – 09.30
3A-PL2-02 JEAN JULLIARD PRIZE AWARD LECTURE
Chairs: F. Décary, chairsperson of the Jean Julliard Prize Committee
E. Seifried, President-elect ISBT

UNIQUE PROPERTIES OF TRANSFUSED ERYTHROCYTES AS INDUCERS OF AND TARGETS FOR THE IMMUNE RESPONSE
J. Zimring (Emory University School of Medicine, Atlanta, GA, USA)

09.30 – 10.00

COFFEE BREAK

10.00 – 11.30 Ballroom G - L

Plenary Session 3: ISBT Presidential Award Symposium
Chairs: S. Takamoto, President of the ISBT
W.G. van Aken, CHairman of the Foundation Transfusion Medicine

10.00 – 10.05
3A-PL3-01 INTRODUCTION
W.G. van Aken (Chairman of the Foundation Transfusion Medicine)

10.05 – 10.30
3A-PL3-02 THE IMPORTANCE OF PLATELET IMMUNOLOGY FOR THE CLINICAL OUTCOME OF PLATELET TRANSFUSIONS
A. Brand (Sanquin, Leiden, The Netherlands)

10.30 – 10.55
3A-PL3-03 DESIGN OF CLINICAL PROTOCOLS FOR EVALUATION OF PLATELET TRANSFUSIONS
N. Heddle (McMaster University, Hamilton, Canada)

10.55 – 11.20
3A-PL3-04 PLATELET TRANSFUSION THERAPY: PRESENT AND FUTURE DIRECTIONS
S. Slichter (Winner of the ISBT Presidential Award)

11.20 – 11.30
3A-PL3-05 PRESENTATION OF THE ISBT PRESIDENTIAL AWARD TO PROF. S.L. SLICHTER
S Takamoto (President of the ISBT)

11.30 – 13.00 Ballroom G - L

ISBT GENERAL ASSEMBLY

13.00 – 15.00

LUNCH BREAK AND SATELLITE SYMPOSIA

Satellite Symposium

13.15 – 14.45 Florence

Satellite Symposium organised by Cerus

SS6: INTERCEPT Pathogen Inactivation: Increasing patient safety and blood availability – a 21st century paradigm shift

Chair: P.V. Holland

PATHOGEN INACTIVATION: THE PARADIGM SHIFT IN TRANSFUSION MEDICINE
P.V. Holland (University of California at Davis School of Medicine, Davis, CA, USA)
THE EUROPEAN EXPERIENCE: INTERCEPT PLATELETS AND PLASMA IN ROUTINE USE
J-P Cazenave (Etablissement Francais du Sang - Alsace, Strasbourg, France)
DEFENCE AGAINST EMERGING PATHOGENS: POTENTIAL IMPACT OF PATHOGEN INACTIVATION ON BLOOD SAFETY AND SUPPLY
M. Koh (Health Sciences Authority, Centre for Transfusion Medicine, Singapore)
THE COMPREHENSIVE POTENTIAL OF PATHOGEN INACTIVATION
J. McCullough (Department of Laboratory Medicine & Pathology, University of Minnesota, Minneapolis, Minnesota, USA)
SUMMARY, Q&A
P.V. Holland (University of California at Davis School of Medicine, Davis, California, USA)

Satellite Symposium

12.15 – 13.45 Sicily

Satellite Symposium organised by Chiron

SS7: Clinical Utility of Multiplex NAT Assays for the Enhancement of Overall Blood Safety

Chair: P. Flanagand

13.15 – 13.20
OPENING REMARKS
P. Flanagan (New Zealand Blood Service, Auckland, New Zealand)

13.20 – 13.50
TRANSFUSION TRANSMITTED VIRAL INFECTIVITY
S. Kleinman (U. British Columbia, Victoria, USA)

13.50 – 14.10
OPERATIONAL IMPLICATIONS OF HBV NAT TESTING
C.K. Lin (Hong Kong Red Cross Blood Transfusion Service, Hong Kong SAR, China)

14.10 – 14.30
APPLICATION OF INDIVIDUAL NAT TESTING IN A HIGH INCIDENCE ENVIRONMENT
M. El Ekiaby (Shabrawishvi Hospital Blood Transfusion Center, Cairo, Egypt)
14.30 – 14.45
PANEL DISCUSSION All

15.00 – 16.40 Ballroom G - L

Parallel Session S16: Seission to be announced

15.00 – 16.35 Milan

Parallel Session S17: Treatment of bleeding complications

15.00 – 15.25
3C-S17-01 EFFICACY AND SAFETY OF PROHEMOSTATIC AGENTS
M. Levi (Academic Medical Center, Amsterdam, The Netherlands)

15.25 – 15.50
3C-S17-02 CRITICAL VIEWS ON FACTOR VIIA
J. Takamatsu (Nagoya University Hospital, Nagoya, Japan)

16.05 – 16.20
3C-S17-03 ROLES OF PLASMA FIBRONECTIN IN THROMBOSIS AND HEMOSTASIS: A LESSON FROM FIBRINOGEN/VWF/AND PLASMA FINRONECTIN TRIPLE KNOCKOUT MICE
H. Ni, A. Reheman, H. Yang, C. Spring, G. Zhu, P. Chen, D. Wagner, R. Fassler, J. Freedman, H. Ni (St. Michael's Hospital, Toronto, Canada)

16.20 – 16.35
3C-S17-04 INTRAVENOUS IGG TRANSFUSION RESTORES ANGIOGENESIS AND AMELIORATES INTRACRANIAL HEMORRHAGE IN FETAL AND NEONATAL ALLOIMMUNE THROMBOCYTOPENIA
H. Yang, P. Chen, S. Boyd, X. Zhao, S. Piran, C. Li, G. Zhu, J. Freedman, H. Ni (Canadian Blood Services/ St. Michael's Hopital, Toronto, Canada)

15.00 – 16.30 Napels

Parallel Session S18: Red Cell Immunology

15.00 – 15.30
3C-S18-01 POST GENOMICS AND THE ERYTHROCYTE MEMBRANE STRUCTURE AND FUNCTION
N. Avent (University of the West of England, Bristol, United Kingdom)

15.30 – 16.00
3C-S18-02 PHYSIOPATHOLOGICAL ROLE OF LUTHERAN BLOOD GROUP GLYCOPROTEINS IN ERYTHROID AND NON ERYTHROID TISSUES
Y. Colin (Inserm, Paris, France)

16.00 – 16.15
3C-S18-03 DUCLOS-NEGATIVE AND OL(A+) BLOOD GROUP PHENOTYPES ARE ASSOCIATED WITH AMINO ACID SUBSTITUTIONS IN THE EXTERNAL LOOPS OF THE RH-ASSOCIATED GLYCOPROTEIN
L. Tilley, A. Gaskell, J. Poole, G. Daniels (Bristol Institute for Transfusion Sciences, Bristol, United Kingdom)

16.15 – 16.30
3C-S18-04 ANTI-GLYCOPHORIN C INDUCES MITOCHONDRIAL MEMBRANE DEPOLARIZATION AND A LOSS OF ERK1/2 ACTIVITY THAT IS REVERSED BY PRE-TREATMENT WITH CYTOCHALASIN D: IMPLICATIONS FOR ANTI-GE3 HDFN
G. Denomme, A. Micieli, D. Wang, J. Fernandes (Canadian Blood Services, Toronto, Canada)

15.00 – 16.30 Florence

Parallel Session S19: Emerging Infections

15.00 – 15.15
3C-S19-01 10-MONTH EXPERIENCE SCREENING USA BLOOD DONORS FOR TRYPANOSOMA CRUZI: YIELD, RISK FACTORS, AND COST EFFECTIVENESS
S. Custer, H.T. Kamel, P.A. Tomasulo, E.L. Murphy, M.P. Busch (Blood Systems Research Institute, San Francisco, USA)

15.15 – 15.30
3C-S19-02 EVALUATING THE EFFECTIVENESS OF MALARIA DEFERRALS THROUGH ANTIBODY TESTING
A. Leiby, L. Nguyen, T. Goff, J. Gibble (American Red Cross, Rockville, MD, USA)

15.30 – 15.45
3C-S19-03 GENETIC VARIABILITY OF WEST NILE VIRUS (WNV) IN CLINICAL ISOLATES FROM U.S.
M. Rios, A. Grinev, C. Chancey, S. Daniel, M. Rios (Food and Drug Administration, Bethesda, USA)

15.45 – 16.00
3C-S19-04 SCREENING OF BLOOD DONORS FOR CHIKUNGUNYA-VIRUS - DEVELOPMENT AND EVALUATION OF MINIPOOL-NAT AND ANTIBODY TESTS
M. Schmidt, M.K. Hourfar, C. Drosten, E. Seifried, M. Panning (German Red Cross, Institute Frankfurt, Frankfurt, Germany)

16.00 – 16.15
3C-S19-05 SIMULATING THE IMPACT OF PANDEMIC INFLUENZA ON THE U.S. BLOOD SUPPLY
O. Walderhaug, M. Menis (U.S. Food & Drug Administration, Rockville, USA)

16.15 – 16.30
3C-S19-06 INTERNATIONAL COLLABORATION IN PANDEMIC INFLUENZA PLANNING - THE ALLIANCE OF BLOOD OPERATORS
A. Fearon, R. Bedford, L. Katz, A. Keller, A. Saunders, T. Selva, R. Sylvester, S. Ward, G. Sher (Canadian Blood Services, Toronto, Canada)

15.00 - 16.30 Sicily

Parallel Session S20: HLA

15.00 – 15.30
3C-S20-01 IMMUNOGENETICS OF STEM CELL TRANSPLANTATION
K. Hsu (Memorial Sloan-Kettering Cancer Center, New York, USA)

15.30 – 16.00
3C-S20-02 IMMUNOGENETICS OF HLA AND KIR
D. Middleton (Northern Ireland Histcompatibility & Immunogenetics Labaratory, Belfast, Ireland)

16.00 – 16.15
3C-S20-03 THE IMMUNOGENETIC SIMILARITY BETWEEN HAEMATOLOGICAL RECIPIENTS AND CORD BLOOD DONORS INCREASES THE CHANCE OF FINDING AN UNRELATED STEM CELL DONOR
A. Pasi, P. Bergamaschi, C. Capittini, A. De Silvestri, C. Badulli, F. Garlaschelli, I. Sbarsi, C. Perotti, M. Cuccia, M. Martinetti, L. Salvaneschi (HLA Laboratory, Transfusion Med. Dept., Fondazione IRCCS Policlinico San Matteo, Pavia, Italy)

16.15 – 16.30
3C-S20-04 SIGNIFICANCE OF HLA AND KIR MATCHING IN STEM CELL TRANSPLANTATION: KILLER CELL IMMUNGLOBULINE LIKE RECEPTOR LIGAND MISMATCHED ALLOGRAFTS IMPROVE THE CLINICAL OUTCOME IN PATIENTS WITH AML
H. Seidl, R. Richter, A. Kraumnitz, G. Bug, H. Serve, E. Seifried, H. Martin, C. Seidl (RCBDS Institute of Transfusion Medicine, Frankfurt Am Main, Germany)